(Reuters) - Pfizer Inc and Eli Lilly and Co will resume a late-stage study testing their pain drug tanezumab after the U.S. Food and Drug Administration lifted a partial hold on it.
Pfizer expects to receive a $200 million upfront payment from Lilly as a result of the development, the companies said on Monday.
23:37 Here’s Why Netflix’s Share Price Just Hit a New All-Time High
21:52 Netflix nears 94 million subscribers 10 years after streaming launch13
11:20 PE firm Warburg buys $121 million stake in Indian cinema operator PVR13
22:33 Allergan to pay $15 million over failing to disclose merger talks18